December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

14.13 +0.36 (+2.61%)
Streaming Delayed Price Updated: 10:45 AM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about NovoCure Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
NovoCure (NVCR) Q4 2024 Earnings Call Transcript ↗
NovoCure (NVCR) Q4 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
NovoCure (NVCR) Q3 2024 Earnings Call Transcript ↗
NovoCure (NVCR) Q3 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Novocure (NVCR) Q2 2025 Earnings Call Transcript ↗
Novocure (NVCR) Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
NovoCure (NVCR) Q3 2025 Earnings Call Transcript ↗
NovoCure (NVCR) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings World Trade
News headline image
Earnings Scheduled For October 30, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For July 24, 2025 ↗
 
Via Benzinga
News headline image
NovoCure Earnings Preview ↗
 
Via Benzinga
News headline image
Earnings Scheduled For April 24, 2025 ↗
 
Via Benzinga
News headline image
NovoCure's Earnings: A Preview ↗
 
Via Benzinga
News headline image
2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon ↗
If you have decades of investing runway left, consider these two top healthcare stocks. 
Via The Motley Fool
News headline image
Novocure (NASDAQ:NVCR) Q3 2025 Earnings: Revenue Beat and Narrower Loss Drive Shares Higher ↗
Novocure (NVCR) beat Q3 2025 revenue estimates and narrowed its loss, with shares rising. The oncology firm is expanding its Tumor Treating Fields therapy into new cancers. 
Via Chartmill
News headline image
2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts ↗
Investment bank analysts up and down Wall Street are pounding the table on these stocks. 
Via The Motley Fool
News headline image
Top 3 Health Care Stocks That May Explode In July ↗
 
Via Benzinga
News headline image
NovoCure Q2 Revenue Jumps 6 Percent ↗
Via The Motley Fool
Topics World Trade
News headline image
Prediction: Novocure (NVCR) Will Beat the Market. Here's Why ↗
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Novocure: Steady Ahead of Key Milestones ↗
Via The Motley Fool
News headline image
This Circle Internet Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
Demystifying NovoCure: Insights From 4 Analyst Reviews ↗
 
Via Benzinga
News headline image
Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio? ↗
 
Via Benzinga
News headline image
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial ↗
TTField therapy with chemotherapy improved median overall and pain-free survival in pancreatic cancer, according to new data from the PANOVA-3 trial. 
Via Benzinga
News headline image
1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street ↗
Via The Motley Fool
News headline image
Why NovoCure Stock Skyrocketed This Week ↗
Via The Motley Fool
Topics Earnings Stocks
News headline image
Why NovoCure Stock Leaped 4% Higher Today ↗
Via The Motley Fool
News headline image
NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025 ↗
NovoCure posted a smaller-than-expected Q1 loss with 12% revenue growth, while monitoring tariff shifts that could impact 2025 costs. 
Via Benzinga
Topics World Trade
News headline image
NovoCure Surpasses Q1 Expectations ↗
NovoCure posted stronger-than-expected Q1 2025 results, driven by revenue and GAAP earnings surpassing estimates. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why NovoCure Stock Was Withering on Wednesday ↗
Via The Motley Fool
News headline image
NovoCure (NVCR) Q4 2024 Earnings Call Transcript ↗
NVCR earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
NovoCure Reports Wider Than Expected Q4 Loss Despite 21% Jump In Sales, Expects Product Enhancements To Hit Gross Margin In 2025 ↗
NovoCure's Q4 revenue rose 21% to $161.27M, surpassing expectations, while its loss widened. Annual sales hit $605M, fueled by Optune Gio's expansion. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.